Company Financial Performance Before and During the Covid-19 Period in the Pharmaceutical Sub-Sector
DOI:
https://doi.org/10.54099/ijebm.v2i1.573Keywords:
Current Ratio, , Debt to Equity Ratio,, Total Assets Turnover,, Return On AssetsAbstract
The Pharmaceutical Industry generates short-term profits that support the need of handling Covid-19. Based on this explanation, this study aims to determine the company's financial performance before and during the Covid-19 pandemic and compare the company’s financial performance before and during the Covid-19 pandemic in the pharmaceutical sub-sector listed on the IDX for the 2018-2021 period. Research using a purposive sampling method. Thus, 10 samples were obtained from 11 pharmaceutical sub-sector companies. The analysis technique used is the normality test, homogenity test, and paired sample t-test. Statistical calculations use the IBM SPSS Statistics 25 application. The results show that the company's financial performance before and during the Covid-19 pandemic in the pharmaceutical sub-sector as measured using the Current Ratio, Debt to Equity Ratio, and Return On Assets have values that are well above the standard. industrial value. While Total Assets Turnover produces a value that is not good below the industry standard value. So that there are 3 conditions of poor company performance such as INAF, KAEF, and PEHA, while there are 7 good company conditions such as DVLA, KLBF, MERK, PYFA, SCPI, SIDO, and TSPC. Comparison of the Current Ratio, Debt to Equity Ratio, Total Assets Turnover, and Return On Assets before and during the Covid-19 pandemic in the pharmaceutical sub-sector listed on the IDX showed no significant differences partially or simultaneously.
References
Abdullah, M. (2014). Manajemen dan Evaluasi Kinerja Karyawan. Aswaja Pressindo.
Asyikin, J., & Tanu, V. S. (2011). Analisis Perbandingan Kinerja Keuangan Antara Perusahaan Farmasi Milik Pemerintah (BUMN) Dengan Perusahaan Farmasi Swasta Yang Terdaftar Di Bursa Efek Indonesia. Jurnal Spread, 1(April).
Athallah, D., Timuriana, T., Fadillah, H., & Pakuan, U. (2022). Analisis Komparasi Kinerja Keuangan Sebelum Dan Selama Pandemi Covid-19 Pada Perusahaan Subsektor Farmasi. JIAFE (Jurnal Ilmiah Akuntansi Fakultas Ekonomi), 8(2), 285–296. https://doi.org/10.34204/jiafe.v8i2.6147
Candrayani, L., Fitri, Z., & Fadlullah Hana, K. (2020). Perbandingan Kinerja Keuangan Perusahaan Farmasi Milik BUMN dan Swasta di BEI Periode 2016-2018. Mabsya: Jurnal Manajemen Bisnis Syariah, 2(1), 19–34. https://doi.org/10.24090/mabsya.v2i1.3877
Candrayani, L., Fitri, Z., & Fadlullah Hana, K. (2021). Perbandingan Kinerja Keuangan Perusahaan Farmasi Milik Bumn Dan Swasta Periode 2016-2018. Jurnal Ilmiah Manajemen “E M O R,” 4(2), 204. https://doi.org/10.32529/jim.v4i2.591
Confindence, I. J., Oloruunleke, F. E., & Olufunke, P. C. (2022). Ownership Structure And Financial Performance Of Listed Pharmaceutical Companies In Nigeria. Research Journal of Management Practice.
DINH, H. T., & PHAM, C. D. (2020). The Effect of Capital Structure on Financial Performance of Vietnamese Listing Pharmaceutical Enterprises. Journal of Asian Finance, Economics, and Business, 329-340.
Fahmi, I. (2014). Analisis Laporan Keuangan. Alfabeta.
Fauzi, S., & Retnosari. (2022). Analisis Komparasi Kinerja Keuangan Perusahaan Farmasi Sebelum dan Saat Pandemi Covid-19. Jurnal Cakrawala Ilmiah, 2(1), 137–148.
Fauzia, M., & Sukmana, Y. (2020). Menurut Sri Mulyani, Ini Sektor yang Untung dan Buntung Selama Pandemi Virus Corona. Kompas.Com. https://money.kompas.com/read/2020/04/06/154211426/menurut-sri-mulyani-ini-sektor-yang-untung-dan-buntung-selama-pandemi-virus?page=allGupta, D. S., & Kotwani, D. S. (2022). A Visualization Approach For Comparing Financial Performance Of Pharmaceutical Companies. Journal of Contemporary Issues in Business and Government, 04.
Gusman, H. (2020). Bagaimana COVID-19 Mengubah Ekonomi Indonesia & ASEAN? Tirto. Id. https://tirto.id/bagaimana-covid-19-mengubah-ekonomi-indonesia-asean-fWjv
Hanafi, M., & Halim, A. (2018). Analisis Laporan Keuangan. UPP STIM YKPN.
Hantono. (2017). Konsep Analisa Laporan Keuangan Dengan Pendekatan Rasio dan SPSS. Deepublish.
Harahap, S. S. (2018). Analisis Kritis atas Laporan Keuangan. PT. Raja Grafindo Persada.
Ilal Hilaliyah, Etty Gurendrawati, & Dwi Handarini. (2021). Analisis Komparatif Kinerja Keuangan Sebelum dan Saat Covid-19 pada Perusahaan yang Terdaftar di BEI. Jurnal Akuntansi, Perpajakan Dan Auditing, 2(3), 641–660. https://doi.org/10.21009/japa.0203.09
Indiraswari, S. D., & Rahmayanti, N. P. (2022). Analisis Perbedaan Kinerja Keuangan Perusahaan Transportasi Di Bei Sebelum Dan Sesudah Pandemi Covid-19. Al-KALAM JURNAL KOMUNIKASI, BISNIS DAN MANAJEMEN, 9(1), 21. https://doi.org/10.31602/al-kalam.v9i1.5109
Indonesia Statistic Bureau. (2020). Katalog: 3101028. Analisis Hasil Survei Dampak COVID-19 Terhadap Pelaku Usaha, vi+ 22 halaman.
Kanchan, D., & Verma, T. (2022). Financial Performance Analysis Of Pharmaceutical Industry In India. International Journal for Multidisciplinary Research (IJFMR), 2582-2160.
Kasmir. (2018). Analisis Laporan Keuangan (11th ed.). PT. Raja Grafindo Persada.
Lopez-Toro, A. A., Sanchez-Teba, E. M., Benitez-Marquez, M. D., & Rodriguez-Fernandez, M. (2021). Influence of ESGC Indicators on Financial Performance of Listed Pharmaceutical Companies. International Journal of Environmental Research and Public Health, 4556
Mardiyani, M. (2017). Analisis Perbandingan Kinerja Keuangan Perusahaan Farmasi Milik Bumn Dan Swasta. Jurnal Inspirasi Bisnis Dan Manajemen, 1(1), 19. https://doi.org/10.33603/jibm.v1i1.486
Maulidi, A. (2016). Teknik Belajar Statistika 2. Alim’s Publishing.
Munawir. (2014). Analisa Laporan Keuangan. Liberty.
Nuryadi. (2017). Dasar-Dasar Statistik Penelitian. Gramasurya.
Nuryaman, & Christina. (2015). Metode Penelitian Akuntansi dan Bisnis Teori & Praktik. Ghalia Indonesia.
Prasetya, V. (2021). Analisis Kinerja Keuangan Perusahaan Sebelum Dan Saat Pandemi Covid 19 Pada Perusahaan Farmasi Yang Tercatat Di Bursa Efek Indonesia. Jurnal Ilmiah Indonesia, 2021(5), 579–587. http://cerdika.publikasiindonesia.id/index.php/cerdika/index10.36418/cerdika.v1i5.92
Prihadi, T. (2019). Analisis Laporan Keuangan. PT. Gramedia Pustaka Utama.
Puspitasari, I., & Rahmawati, W. T. (2020). Kinerja emiten farmasi mengilap di semester pertama 2020. Kontan. Co.Id. https://investasi.kontan.co.id/news/kinerja-emiten-farmasi-mengilap-di-semester-pertama-2020?page=2
Ross, S. A., Westerfield, R. W., & Jaffe, J. (2018). Corporate Finance. Corporate Finance. https://doi.org/10.31085/9785392288236-2019-640
Rudianto, D. (2015). COMPARISON OF FINANCIAL PERFORMANCE AND STOCK PRICE BEFORE AND AFTER EX - DIVIDEND LISTED COMPANIES IN INDONESIA. 11(1), 185–196.
Rudianto, D. (2021). Measuring the financial performance prior to and after the initial public offering (IPO) of companies listed in the Indonesian stock exchange (IDX). International Conference on Strategic Issues of Economics, Business, and Education (ICoSIEBE 2020), 231-237.
Septian, D., & Diana PD, N. P. (2021). Analisis Perbedaan Kinerja Keuangan Sebelum dan Setelah Akuisisi pada Perusahaan di Bursa Efek Indonesia. Digilibadmin.Unismuh. Ac.Id, 2(1), 1–114. https://doi.org/10.54259/akua.v2i1.1422
Sugiyono. (2017). Metode Penelitian Kombinasi (Mixed Method). PT. Alfabeta.
Suryanto, V., & Mahadi, T. (2020). Pengaruh Covid-19 ke perekonomian Indonesia diklaim tak separah di negara lain. Kontan. Co.Id. https://nasional.kontan.co.id/news/pengaruh-covid-19-ke-perekonomian-indonesia-diklaim-tak-separah-di-negara-lain
Ugo, C. C., & Egbuhuzor, C. A. (2022). Effect Of Cashflow Management On Financial Performance: Evidence From The Pharmaceutical Industry In Nigeria. African Journal of Accounting and Financial Research.
ZAVINCU, A. I. (2022). Comparative Analysis Of Key Performance Indicators Of Major Brands In The Romanian Pharmaceutical Industry. Hyperion Economic Journal.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 International Journal of Entrepreneurship and Business Management
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
